RU97102162A - METHOD OF SYNTHESIS OF SUBSTITUTED SULPHOXIDES - Google Patents
METHOD OF SYNTHESIS OF SUBSTITUTED SULPHOXIDESInfo
- Publication number
- RU97102162A RU97102162A RU97102162/04A RU97102162A RU97102162A RU 97102162 A RU97102162 A RU 97102162A RU 97102162/04 A RU97102162/04 A RU 97102162/04A RU 97102162 A RU97102162 A RU 97102162A RU 97102162 A RU97102162 A RU 97102162A
- Authority
- RU
- Russia
- Prior art keywords
- het
- hydrogen
- alkyl
- halogen
- alkoxy
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims 5
- 238000003786 synthesis reaction Methods 0.000 title claims 5
- 230000002194 synthesizing Effects 0.000 title claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical group 0.000 claims 16
- -1 sulfoxide compounds Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 12
- 229910052719 titanium Inorganic materials 0.000 claims 12
- 239000010936 titanium Substances 0.000 claims 12
- 150000003462 sulfoxides Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000002585 base Substances 0.000 claims 5
- 239000003960 organic solvent Substances 0.000 claims 5
- 239000007800 oxidant agent Substances 0.000 claims 5
- 150000003568 thioethers Chemical class 0.000 claims 5
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims 4
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000002829 nitrogen Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1H-benzimidazol-2-ylsulfinylmethyl)-N-methyl-N-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims 1
- YQHLDYVWEZKEOX-UHFFFAOYSA-N Cumene hydroperoxide Chemical compound OOC(C)(C)C1=CC=CC=C1 YQHLDYVWEZKEOX-UHFFFAOYSA-N 0.000 claims 1
- YSAVZVORKRDODB-WDSKDSINSA-N Diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 claims 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N Titanium isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 239000012043 crude product Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000005712 crystallization Effects 0.000 claims 1
- YSAVZVORKRDODB-PHDIDXHHSA-N diethyl (2R,3R)-2,3-dihydroxybutanedioate Chemical compound CCOC(=O)[C@H](O)[C@@H](O)C(=O)OCC YSAVZVORKRDODB-PHDIDXHHSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- IDNZVRFVPNWKPA-UHFFFAOYSA-N CCNc1c(CC(C2)=Nc3c2cccc3)cccc1 Chemical compound CCNc1c(CC(C2)=Nc3c2cccc3)cccc1 IDNZVRFVPNWKPA-UHFFFAOYSA-N 0.000 description 1
- 0 Cc(c(C*)c1*)ccc1I Chemical compound Cc(c(C*)c1*)ccc1I 0.000 description 1
- TYRULXQNYUUGCF-UHFFFAOYSA-N Cc1c(C=O)c(C)c(CC(C2)=Nc3c2ccc(C=O)c3)cc1 Chemical compound Cc1c(C=O)c(C)c(CC(C2)=Nc3c2ccc(C=O)c3)cc1 TYRULXQNYUUGCF-UHFFFAOYSA-N 0.000 description 1
Claims (1)
где Het1 является
Het2 является
X является
где N внутри бензольного кольца бензимидазольной составляющей означает, что один из атомов углерода, замещенных R6-R9, необязательно может быть заменен на атом азота без каких-либо заместителей;
R1, R2 и R3 являются одинаковыми или разными и их выбирают из водорода, алкила, алкилтио, алкокси, необязательно замещенных фтором, алкоксиалкокси, диалкиламино, пиперидино, морфолино, галогеном, фенилалкилом и фенилалкокси;
R4 и R5 являются одинаковыми или разными и их выбирают из водорода, алкила и аралкила;
R6 является водородом, галогеном, трифторметилом, алкилом и алкокси;
R6-R9 являются одинаковыми или разными и их выбирают из водорода, алкила, алкоксила, галогена, галогеналкоксила, алкилкарбонила, алкоксикарбонила, оксазолила, трифторалкила или соседние группы R6-R9, образуют кольцевые структуры, которые могут быть дополнительно замещены;
R10 является водородом или вместе с R3 образует алкиленовую цепь;
R11 и R12 являются одинаковыми или разными и их выбирают из водорода, галогена или алкила, и алкильные группы, алкоксигруппы и их составляющие могут быть разветвленными или прямыми C1-C9 цепями или включать циклические алкильные группы, например циклоалкилалкильные,
отличающийся тем, что прохиральный сульфид формулы II
Het1-X-S-Het2,
где Het1 и Het2 являются такими, как они определены выше,
окисляют в органическом растворителе окисляющим агентом в присутствии хирального комплексного соединения титана и основания, и полученный сульфоксид необязательно превращают в его фармацевтически приемлемую соль обычными способами.1. The way enantioselective synthesis of sulfoxide compounds of formula I or its alkali salt in the form of a single enantiomer or in enantiomerically enriched form:
where het 1 is
Het 2 is
X is
where N inside the benzene ring of the benzimidazole moiety means that one of the carbon atoms substituted by R 6 -R 9 can optionally be replaced with a nitrogen atom without any substituents;
R 1 , R 2 and R 3 are the same or different and are selected from hydrogen, alkyl, alkylthio, alkoxy, optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;
R 4 and R 5 are the same or different and are selected from hydrogen, alkyl and aralkyl;
R 6 is hydrogen, halogen, trifluoromethyl, alkyl, and alkoxy;
R 6 -R 9 are the same or different and are selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or neighboring groups R 6 -R 9 , form ring structures that can be further substituted;
R 10 is hydrogen or together with R 3 forms an alkylene chain;
R 11 and R 12 are the same or different and are selected from hydrogen, halogen or alkyl, and alkyl groups, alkoxy groups and their components can be branched or straight C 1 -C 9 chains or include cyclic alkyl groups, for example cycloalkylalkyl,
wherein the pro-chiral sulfide of formula II
Het 1 -XS-Het 2 ,
where Het 1 and Het 2 are as defined above,
is oxidized in an organic solvent with an oxidizing agent in the presence of a chiral complex compound of titanium and a base, and the resulting sulfoxide is optionally converted to its pharmaceutically acceptable salt by conventional means.
где Het1 является
Het2 является
X является
где N внутри бензольного кольца бензимидазольной составляющей означает, что один из атомов углерода, замещенных R6-R9, необязательно может быть заменен на атом азота без каких-либо заместителей;
R1, R2 и R3 являются одинаковыми или разными и их выбирают из водорода, алкила, алкилтио, алкокси, необязательно замещенных фтором, алкоксиалкокси, диалкиламино, пиперидино, морфолино, галогеном, фенилалкилом и фенилалкокси;
R4 и R5 являются одинаковыми или разными и их выбирают из водорода, алкила и аралкила;
R6 является водородом, галогеном, трифторметилом, алкилом и алкокси;
R6-R9 являются одинаковыми или разными и их выбирают из водорода, алкила, алкоксила, галогена, галогеналкоксила, алкилкарбонила, алкоксикарбонила, оксазолила, трифторалкила, или соседние группы R6-R9, образуют кольцевые структуры, которые могут быть дополнительно замещены;
R10 является водородом или вместе с R3 образует алкиленовую цепь;
R11 и R12 являются одинаковыми или разными и их выбирают из водорода, галогена или алкила, и алкильные группы, алкоксильные группы и их составляющие могут быть разветвленными или прямыми C1-C9 цепями или включать циклические алкильные группы, например циклоалкилалкильные,
отличающийся тем, что прохиральный сульфид формулы II
Het1-X-S-Het2, (II)
где Het1 и Het2 являются такими, как они определены выше,
окисляют в органическом растворителе окисляющим агентом в присутствии хирального комплексного соединения титана, необязательно в присутствии основания, где комплексное соединение титана получают в присутствии прохирального сульфида и полученный сульфоксид необязательно превращают в фармацевтически приемлемую соль обычными способами.2. The way enantioselective synthesis of sulfoxide of the formula I in the form of a single enantiomer or in enantiomerically enriched form:
where het 1 is
Het 2 is
X is
where N inside the benzene ring of the benzimidazole moiety means that one of the carbon atoms substituted by R 6 -R 9 can optionally be replaced with a nitrogen atom without any substituents;
R 1 , R 2 and R 3 are the same or different and are selected from hydrogen, alkyl, alkylthio, alkoxy, optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;
R 4 and R 5 are the same or different and are selected from hydrogen, alkyl and aralkyl;
R 6 is hydrogen, halogen, trifluoromethyl, alkyl, and alkoxy;
R 6 -R 9 are the same or different and are selected from hydrogen, alkyl, alkoxy, halogen, halogenoalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or neighboring groups R 6 -R 9 form ring structures that can be further substituted;
R 10 is hydrogen or together with R 3 forms an alkylene chain;
R 11 and R 12 are the same or different and are selected from hydrogen, halogen or alkyl, and alkyl groups, alkoxy groups and their components can be branched or straight C 1 -C 9 chains or include cyclic alkyl groups, for example cycloalkylalkyl,
wherein the pro-chiral sulfide of formula II
Het 1 -XS-Het 2 , (II)
where Het 1 and Het 2 are as defined above,
oxidized in an organic solvent with an oxidizing agent in the presence of a chiral complex compound of titanium, optionally in the presence of a base, where the complex compound of titanium is obtained in the presence of prochiral sulphide and the resulting sulfoxide is optionally converted into a pharmaceutically acceptable salt by conventional means.
где Het1 является:
Het2 является:
X является:
где N внутри бензольного кольца бензимидазольной составляющей означает, что один из атомов углерода, замещенных R6-R9, необязательно может быть заменен на атом азота без каких-либо заместителей;
R1, R2 и R3 являются одинаковыми или разными и их выбирают из водорода, алкила, алкилтио, алкокси, необязательно замещенных фтором, алкоксиалкокси, диалкиламино, пиперидино, морфолино, галогеном, фенилалкилом и фенилалкокси;
R4 и R5 являются одинаковыми или разными и их выбирают из водорода, алкила и аралкила;
R6 является водородом, галогеном, трифторметилом, алкилом и алкокси;
R6-R9 являются одинаковыми или разными и их выбирают из водорода, алкила, алкоксила, галогена, галогеналкоксила, алкилкарбонила, алкоксикарбонила, оксазолила, трифторалкила или соседние группы R6-R9, образуют кольцевые структуры, которые могут быть дополнительно замещены,
R10 является водородом или вместе с R3 образует алкиленовую цепь;
R11 и R12 являются одинаковыми или разными и их выбирают из водорода, галогена или алкила, и алкильные группы, алкоксильные группы и их составляющие могут быть разветвленными или прямыми C1-C9 цепями или могут включать циклические алкильные группы, например циклоалкилалкильные,
отличающийся тем, что прохиральный сульфид формулы II
Het1-X-S-Het2, (II)
где Het1 и Het2 являются такими, как они определены выше,
окисляют в органическом растворителе окисляющим агентом в присутствии хирального комплексного соединения титана, необязательно в присутствии основания, где комплексное соединение титана получают при повышенной температуре и/или в течение продолжительного периода получения, и полученный сульфоксид необязательно превращают в фармацевтически приемлемую соль обычными способами.3. The method of enantioselective synthesis of sulfoxide of the formula in the form of a single enantiomer or in enantiomerically enriched form:
where het 1 is:
Het 2 is:
X is:
where N inside the benzene ring of the benzimidazole moiety means that one of the carbon atoms substituted by R 6 -R 9 can optionally be replaced with a nitrogen atom without any substituents;
R 1 , R 2 and R 3 are the same or different and are selected from hydrogen, alkyl, alkylthio, alkoxy, optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;
R 4 and R 5 are the same or different and are selected from hydrogen, alkyl and aralkyl;
R 6 is hydrogen, halogen, trifluoromethyl, alkyl, and alkoxy;
R 6 -R 9 are the same or different and are selected from hydrogen, alkyl, alkoxy, halogen, halogenoalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or neighboring groups R 6 -R 9 form ring structures that can be further substituted,
R 10 is hydrogen or together with R 3 forms an alkylene chain;
R 11 and R 12 are the same or different and are selected from hydrogen, halogen or alkyl, and alkyl groups, alkoxy groups and their components may be branched or straight C 1 -C 9 chains or may include cyclic alkyl groups, for example cycloalkylalkyl,
wherein the pro-chiral sulfide of formula II
Het 1 -XS-Het 2 , (II)
where Het 1 and Het 2 are as defined above,
oxidized in an organic solvent with an oxidizing agent in the presence of a chiral complex compound of titanium, optionally in the presence of a base, where the complex compound of titanium is obtained at elevated temperature and / or for an extended production period, and the resulting sulfoxide is optionally converted into a pharmaceutically acceptable salt by conventional means.
где Het1 является:
Het2 является:
X является:
где N внутри бензольного кольца бензимидазольной составляющей означает, что один из атомов углерода, замещенных R6-R9, необязательно может быть заменен на атом азота без каких-либо заместителей;
R1, R2 и R3 являются одинаковыми или разными и их выбирают из водорода, алкила, алкилтио, алкокси, необязательно замещенных фтором, алкоксиалкокси, диалкиламино, пиперидино, морфолино, галогеном, фенилалкилом и фенилалкокси;
R4 и R5 являются одинаковыми или разными и их выбирают из водорода, алкила и аралкила;
R6 является водородом, галогеном, трифторметилом, алкилом и алкокси;
R6-R9 являются одинаковыми или разными и их выбирают из водорода, алкила, алкоксила, галогена, галогеналкоксила, алкилкарбонила, алкоксикарбонила, оксазолила, трифторалкила или соседние группы R6-R9, образуют кольцевые структуры, которые могут быть дополнительно замещены;
R10 является водородом или вместе с R3 образует алкиленовую цепь;
R11 и R12 являются одинаковыми или разными и их выбирают из водорода, галогена или алкила, и алкильные группы, алкоксильные группы и их составляющие могут быть разветвленными или прямыми C1-C9 цепями или включать циклические алкильные группы, например циклоалкилалкильные,
отличающийся тем, что прохиральный сульфид формулы II
Het1-X-S-Het2, (II)
где Het1 и Het2 являются такими, как они определены выше,
окисляют в органическом растворителе окисляющим агентом в присутствии хирального комплексного соединения титана, необязательно в присутствии основания, где комплексное соединение титана получают в присутствии прохирального сульфида при повышенной температуре и/или в течение продолжительного периода получения, и полученный сульфоксид необязательно превращают в фармацевтически приемлемую соль обычными способами.4. The method of enantioselective synthesis of sulfoxide of formula I in the form of a single enantiomer or in enantiomerically enriched form:
where het 1 is:
Het 2 is:
X is:
where N inside the benzene ring of the benzimidazole moiety means that one of the carbon atoms substituted by R 6 -R 9 can optionally be replaced with a nitrogen atom without any substituents;
R 1 , R 2 and R 3 are the same or different and are selected from hydrogen, alkyl, alkylthio, alkoxy, optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;
R 4 and R 5 are the same or different and are selected from hydrogen, alkyl and aralkyl;
R 6 is hydrogen, halogen, trifluoromethyl, alkyl, and alkoxy;
R 6 -R 9 are the same or different and are selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or neighboring groups R 6 -R 9 , form ring structures that can be further substituted;
R 10 is hydrogen or together with R 3 forms an alkylene chain;
R 11 and R 12 are the same or different and are selected from hydrogen, halogen or alkyl, and alkyl groups, alkoxy groups and their components can be branched or straight C 1 -C 9 chains or include cyclic alkyl groups, for example cycloalkylalkyl,
wherein the pro-chiral sulfide of formula II
Het 1 -XS-Het 2 , (II)
where Het 1 and Het 2 are as defined above,
oxidized in an organic solvent with an oxidizing agent in the presence of a chiral complex compound of titanium, optionally in the presence of a base, where the complex compound of titanium is obtained in the presence of prochiral sulphide at elevated temperature and / or for an extended production period, and the sulfoxide is optionally converted into a pharmaceutically acceptable salt by conventional methods .
где Ar является
R1-R10 являются такими, как они определены в любом из пп. 1-4.5. A method according to any one of claims. 1-4, in which the obtained sulfoxidov are sulfoxidov defined by formula I, in the form of a single enantiomer or in enantiomerically enriched form:
where ar is
R 1 -R 10 are as defined in any of paragraphs. 1-4.
7. Способ по любому из пп. 1-4, отличающийся тем, что прохиральный сульфид формулы II окисляют окисляющим агентом в форме гидропероксида кумола.6. A method according to any one of claims. 1-4, in which the obtained sulfoxidov are sulfoxidov according to any of formulas (Ia) - (Ih) in the form of a single enantiomer or in the form enantiomerically enriched form:
7. A method according to any one of claims. 1-4, characterized in that the prochiral sulfide of formula II is oxidized with an oxidizing agent in the form of cumene hydroperoxide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9402510A SE504459C2 (en) | 1994-07-15 | 1994-07-15 | Process for the preparation of substituted sulfoxides |
SE9402510-3 | 1994-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97102162A true RU97102162A (en) | 1999-03-10 |
RU2157806C2 RU2157806C2 (en) | 2000-10-20 |
Family
ID=20394753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97102162/04A RU2157806C2 (en) | 1994-07-15 | 1995-07-03 | Method of synthesis of substituted sulpoxides |
Country Status (42)
Country | Link |
---|---|
US (1) | US5948789A (en) |
EP (1) | EP0773940B2 (en) |
JP (1) | JP3795917B2 (en) |
KR (1) | KR100356252B1 (en) |
CN (1) | CN1070489C (en) |
AR (1) | AR003443A1 (en) |
AT (1) | ATE242233T1 (en) |
AU (1) | AU688074B2 (en) |
BR (1) | BR9508292A (en) |
CA (1) | CA2193994C (en) |
CZ (1) | CZ297987B6 (en) |
DE (1) | DE69530987T3 (en) |
DK (1) | DK0773940T4 (en) |
DZ (1) | DZ1911A1 (en) |
EE (1) | EE03354B1 (en) |
EG (1) | EG24534A (en) |
ES (1) | ES2199998T5 (en) |
FI (2) | FI117672B (en) |
HK (1) | HK1008331A1 (en) |
HR (1) | HRP950401B1 (en) |
HU (1) | HU226361B1 (en) |
IL (1) | IL114477A (en) |
IS (1) | IS1772B (en) |
MA (1) | MA23611A1 (en) |
MX (1) | MX9700358A (en) |
MY (1) | MY113180A (en) |
NO (1) | NO312101B1 (en) |
NZ (1) | NZ289959A (en) |
PL (1) | PL186342B1 (en) |
PT (1) | PT773940E (en) |
RU (1) | RU2157806C2 (en) |
SA (1) | SA95160294B1 (en) |
SE (1) | SE504459C2 (en) |
SI (1) | SI0773940T2 (en) |
SK (1) | SK284059B6 (en) |
TN (1) | TNSN95081A1 (en) |
TR (1) | TR199500861A2 (en) |
TW (1) | TW372971B (en) |
UA (1) | UA47409C2 (en) |
WO (1) | WO1996002535A1 (en) |
YU (1) | YU49475B (en) |
ZA (1) | ZA955724B (en) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9301830D0 (en) * | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE504459C2 (en) * | 1994-07-15 | 1997-02-17 | Astra Ab | Process for the preparation of substituted sulfoxides |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
SE510650C2 (en) | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
SE510643C2 (en) * | 1997-06-27 | 1999-06-14 | Astra Ab | Thermodynamically stable omeprazole sodium form B |
IL133800A0 (en) | 1997-07-03 | 2001-04-30 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9704183D0 (en) * | 1997-11-14 | 1997-11-14 | Astra Ab | New process |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
JP2002501897A (en) * | 1998-01-30 | 2002-01-22 | セプラコール, インク. | R-lansoprazole compositions and methods |
WO1999055157A1 (en) * | 1998-04-30 | 1999-11-04 | Sepracor Inc. | R-rabeprazole compositions and methods |
JP2002512263A (en) * | 1998-04-30 | 2002-04-23 | セプラコール, インク. | S-Raybprazole compositions and methods |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
CN1087739C (en) * | 1998-12-28 | 2002-07-17 | 中国科学院成都有机化学研究所 | Inclusion and resolution preparation process of optical purity benzimidazoles medicines resisting peptic ulcer |
SE9900274D0 (en) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
TWI289557B (en) | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
EP1191025B1 (en) * | 1999-06-30 | 2005-06-22 | Takeda Pharmaceutical Company Limited | Crystals of lansoprazole |
WO2001014366A1 (en) * | 1999-08-25 | 2001-03-01 | Takeda Chemical Industries, Ltd. | Process for the preparation of optically active sulfoxide derivatives |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
CA2407208C (en) * | 2000-04-28 | 2010-08-17 | Takeda Chemical Industries, Ltd. | Process for producing optically active sulfoxide derivative |
KR100869677B1 (en) | 2000-05-15 | 2008-11-21 | 다케다 야쿠힌 고교 가부시키가이샤 | Process for producing crystal |
ES2511774T3 (en) | 2000-05-15 | 2014-10-23 | Takeda Pharmaceutical Company Limited | Crystal forms of (R) -lansoprazole |
WO2002012225A1 (en) | 2000-08-04 | 2002-02-14 | Takeda Chemical Industries, Ltd. | Salts of benzimidazole compound and use thereof |
HU229356B1 (en) * | 2000-12-01 | 2013-11-28 | Takeda Pharmaceutical | Process for the crystallization of (r)- or (s)-lansoprazole |
JP2004536049A (en) * | 2001-04-13 | 2004-12-02 | アプシンターム・リミテッド・ライアビリティ・カンパニー | Method for producing sulfinamide and sulfoxide |
GB2376231A (en) * | 2001-06-06 | 2002-12-11 | Cipla Ltd | Benzimidazole-cyclodextrin inclusion complex |
JP2005521662A (en) * | 2002-01-25 | 2005-07-21 | サンタラス インコーポレイティッド | Transmucosal delivery of proton pump inhibitors |
ES2286408T3 (en) | 2002-03-05 | 2007-12-01 | Astrazeneca Ab | SALES OF ALQUILAMONIO DE OMEPRAZOL E ESOMEPRAZOL. |
AU2003262375A1 (en) * | 2002-04-22 | 2003-11-03 | Sun Pharmaceutical Industries Limited | Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts |
US7169793B2 (en) | 2002-06-27 | 2007-01-30 | Dr. Reddy's Laboratories Limited | Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
ES2534713T3 (en) * | 2002-10-16 | 2015-04-27 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
US20040235903A1 (en) | 2002-10-22 | 2004-11-25 | Khanna Mahavir Singh | Amorphous form of esomeprazole salts |
DE10254167A1 (en) | 2002-11-20 | 2004-06-09 | Icon Genetics Ag | Process for the control of cellular processes in plants |
US7301030B2 (en) * | 2002-12-06 | 2007-11-27 | Nycomed Gmbh | Process for preparing (S)-pantoprazole |
NZ540815A (en) * | 2002-12-06 | 2008-03-28 | Nycomed Gmbh | Process for preparing optically pure active compounds |
AR046245A1 (en) * | 2002-12-16 | 2005-11-30 | Ranbaxy Lab Ltd | RABEPRAZOL CALCIUM SALTS |
FR2848555B1 (en) | 2002-12-16 | 2006-07-28 | Negma Gild | ENANTIOMER (-) OF TENATOPRAZOLE AND ITS THERAPEUTIC APPLICATION |
US7507829B2 (en) | 2002-12-19 | 2009-03-24 | Teva Pharmaceuticals Industries, Ltd | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
EP1583507A2 (en) * | 2003-01-07 | 2005-10-12 | Ranbaxy Laboratories Limited | Magnesium salt of imidazole derivative |
WO2004073654A2 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
CN1777598A (en) * | 2003-02-28 | 2006-05-24 | 兰贝克赛实验室有限公司 | Polymorphs of s-omeprazole. |
ES2245277T1 (en) * | 2003-03-12 | 2006-01-01 | Teva Pharmaceutical Industries Limited | SOLIDOS CRYSTALS AND AMORPHES OF PANTOPRAZOL AND PROCEDURES FOR THEIR PREPARATION. |
EP1611901B1 (en) * | 2003-03-13 | 2013-07-10 | Eisai R&D Management Co., Ltd. | Preventive or remedy for teeth grinding |
FR2852956B1 (en) * | 2003-03-28 | 2006-08-04 | Negma Gild | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF SULFOXIDE DERIVATIVES |
WO2004087702A2 (en) * | 2003-03-28 | 2004-10-14 | Sidem Pharma | Method for the enantioselective preparation of sulphoxide derivatives |
EP1633736A1 (en) * | 2003-05-05 | 2006-03-15 | Ranbaxy Laboratories Limited | Barium salt of benzimidazole derivative |
MXPA05013316A (en) | 2003-06-10 | 2006-03-17 | Teva Pharma | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole. |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
SE0302382D0 (en) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts II |
SE0302381D0 (en) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts I |
AU2003288703A1 (en) * | 2003-12-05 | 2005-06-24 | Hetero Drugs Limited | A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers |
SE0400410D0 (en) | 2004-02-20 | 2004-02-20 | Astrazeneca Ab | New compounds |
PT1740571E (en) | 2004-04-28 | 2009-09-02 | Hetero Drugs Ltd | A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
DE602004025386D1 (en) * | 2004-05-28 | 2010-03-18 | Hetero Drugs Ltd | NEW STEREOSELECTIVE SYNTHESIS OF BENZIMIDAZOLSULFOXIDEN |
BRPI0511515A (en) * | 2004-06-02 | 2007-12-26 | Altana Pharma Ag | process for the preparation of pyridin-2-ylmethylsulfinyl-1h-benzimidazole compounds |
AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
KR20130038949A (en) * | 2004-06-24 | 2013-04-18 | 아스트라제네카 아베 | New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt |
WO2006001755A1 (en) * | 2004-06-24 | 2006-01-05 | Astrazeneca Ab | A new esomeprazole sodium salt crystal modification |
FR2876101B1 (en) * | 2004-10-05 | 2007-03-02 | Sidem Pharma Sa Sa | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF SULFOXIDE DERIVATIVES |
WO2006040635A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | Processes for the preparation of substituted sulfoxides |
US7592111B2 (en) * | 2004-11-05 | 2009-09-22 | Xerox Corporation | Imaging member |
WO2006099810A1 (en) | 2005-03-25 | 2006-09-28 | Livzon Pharmaceutical Group Inc. | Substituted sulfoxide compounds, methods for preparing the same and use thereof |
CN101098867B (en) * | 2005-03-25 | 2010-08-11 | 丽珠医药集团股份有限公司 | Substituted sulfoxide compound and its preparing method and application |
KR20080007508A (en) * | 2005-05-06 | 2008-01-21 | 그렌마크 파머수티칼스 엘티디. | Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same |
WO2006131338A2 (en) * | 2005-06-08 | 2006-12-14 | Lek Pharmaceuticals D.D. | Crystalline solvate of omeprazole sodium |
US20070043085A1 (en) * | 2005-08-19 | 2007-02-22 | Glenmark Pharmaceuticals Limited | Process for the preparation of amorphous form of neutral esomeprazole |
CN101321746A (en) * | 2005-12-05 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | New process for the preparation of esomeprazole non-salt form |
DE102005061720B3 (en) * | 2005-12-22 | 2006-10-19 | Ratiopharm Gmbh | Preparing optically active omeprazole enantiomers, useful to treat stomach diseases, comprises oxidizing prochiral sulfide compound with oxidizing agent in presence of titanium complex catalyst and reacting the catalyst with chiral diols |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US7553857B2 (en) | 2005-12-23 | 2009-06-30 | Lek Pharmaceuticals D.D. | S-omeprazole magnesium |
WO2007074099A1 (en) | 2005-12-28 | 2007-07-05 | Unión Químico Farmacéutica, S.A. | A process for the preparation of the (s)-enantiomer of omeprazole |
CN1810803B (en) * | 2006-02-17 | 2010-11-17 | 中国科学院上海有机化学研究所 | Method for high enantiomer selection preparation of (S)-Omeprazole |
US7579476B2 (en) * | 2006-02-24 | 2009-08-25 | Praktikatalyst Pharma, Llc | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals |
US8063074B2 (en) * | 2006-05-04 | 2011-11-22 | Dr. Reddy's Laboratories Limited | Polymorphic forms of esomeprazole sodium |
US7786309B2 (en) * | 2006-06-09 | 2010-08-31 | Apotex Pharmachem Inc. | Process for the preparation of esomeprazole and salts thereof |
MY148301A (en) | 2006-07-05 | 2013-03-29 | Lupin Ltd | Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds |
US8173818B2 (en) | 2006-08-08 | 2012-05-08 | Jubilant Organosys Limited | Process for producing sulphoxide compounds |
US20110009624A9 (en) | 2006-10-13 | 2011-01-13 | Masato Ueda | Benzimidazole compounds having gastric acid secretion inhibitory action |
JP2009196894A (en) * | 2006-10-13 | 2009-09-03 | Eisai R & D Management Co Ltd | Method for producing sulfinyl benzimidazole compound or salt thereof |
EP1947099A1 (en) | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
NZ579136A (en) | 2007-02-21 | 2012-05-25 | Cipla Ltd | Process for the preparation of esomeprazole magnesium dihydrate |
WO2008149204A1 (en) * | 2007-06-07 | 2008-12-11 | Aurobindo Pharma Limited | An improved process for preparing an optically active proton pump inhibitor |
CN101323609B (en) * | 2007-06-15 | 2013-05-01 | 成都福瑞生物工程有限公司 | Method for synthesizing high antipode content benzimidazole derivative by unsymmetrical oxidizing thioether into sulphoxide |
US20100210848A1 (en) * | 2007-10-03 | 2010-08-19 | Ipca Laboratories Ltd. | Process for optically active sulfoxide compounds |
WO2009047775A2 (en) | 2007-10-08 | 2009-04-16 | Hetero Drugs Limited | Polymorphs of esomeprazole salts |
JP5629581B2 (en) | 2007-10-12 | 2014-11-19 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | Method for treating digestive disorders independent of food intake |
FR2925899B1 (en) * | 2007-12-27 | 2012-12-21 | Sidem Pharma Sa | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF SULFOXIDES. |
CN101492459B (en) * | 2008-01-25 | 2011-04-27 | 山东轩竹医药科技有限公司 | Compound containing alcoxyl acetyl dihydrogen isoxazole-pyridine |
CN101497603B (en) * | 2008-01-30 | 2012-11-07 | 山东轩竹医药科技有限公司 | Benzimidazole derivative containing alkoxy alkanamine oxyl substituted pyridine |
UA103189C2 (en) | 2008-03-10 | 2013-09-25 | Такеда Фармасьютикал Компани Лимитед | Crystal of benzimidazole compound |
EP2265605A4 (en) * | 2008-03-18 | 2011-08-03 | Reddys Lab Ltd Dr | Dexlansoprazole process and polymorphs |
CN101538264A (en) * | 2008-03-19 | 2009-09-23 | 中国科学院成都有机化学有限公司 | Novel method for preparing chiral sulphoxide compound |
WO2009145368A1 (en) * | 2008-05-27 | 2009-12-03 | Sk Chemicals Co., Ltd. | Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent |
EP2143722A1 (en) | 2008-07-09 | 2010-01-13 | Lek Pharmaceuticals D.D. | Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium |
US20100113527A1 (en) * | 2008-09-30 | 2010-05-06 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of dexlansoprazole |
EP2264024A1 (en) | 2008-10-14 | 2010-12-22 | LEK Pharmaceuticals d.d. | Process for the preparation of enantiomerically enriched proton pump inhibitors |
IT1391776B1 (en) | 2008-11-18 | 2012-01-27 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF DEXLANSOPRAZOL |
CZ200990A3 (en) * | 2009-02-16 | 2010-08-25 | Zentiva, K.S. | Process for preparing (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole |
WO2010097583A1 (en) | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
CZ2009172A3 (en) * | 2009-03-17 | 2010-09-29 | Zentiva, K.S. | Process for preparing (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole |
EP2438057A4 (en) * | 2009-06-02 | 2013-12-25 | Sun Pharmaceutical Ind Ltd | Process for preparing sulphoxide compounds |
IT1395118B1 (en) | 2009-07-29 | 2012-09-05 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE |
EP2499125B1 (en) | 2009-11-12 | 2016-01-27 | Hetero Research Foundation | Process for the resolution of omeprazole |
WO2011092665A1 (en) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline forms of dexlansoprazole |
EP2585450A1 (en) | 2010-06-24 | 2013-05-01 | Cilpa Limited | Salts and polymorphs of dexrabeprazole |
CN101914090B (en) * | 2010-08-13 | 2013-03-20 | 埃斯特维华义制药有限公司 | Method for preparing levo-omeprazole |
CN102558150B (en) * | 2010-12-31 | 2014-03-12 | 正大天晴药业集团股份有限公司 | Synthesis process for sulfoxide substituted compound |
CN102321071B (en) * | 2011-07-20 | 2013-01-23 | 江苏奥赛康药业股份有限公司 | Industrial production method of high-purity esomeprazole sodium |
CN102977076A (en) * | 2011-09-02 | 2013-03-20 | 扬子江药业集团上海海尼药业有限公司 | Preparation method of dexlansoprazole |
CN102329302A (en) * | 2011-10-22 | 2012-01-25 | 刘强 | Method for preparing esomeprazole and salts thereof |
CN102408412A (en) * | 2011-10-25 | 2012-04-11 | 广东华南药业集团有限公司 | (S)-omeprazole preparation method with high antipode selectivity |
CN102432412A (en) * | 2011-10-28 | 2012-05-02 | 成都欣捷高新技术开发有限公司 | Preparation method of chiral sulphoxide proton pump inhibitor or pharmaceutically-acceptable salt thereof |
KR101300950B1 (en) * | 2011-10-31 | 2013-08-27 | 르노삼성자동차 주식회사 | Air intake apparatus of an electric vehicle |
WO2013140120A1 (en) | 2012-03-22 | 2013-09-26 | Cipla Limited | Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole |
CN102633776B (en) * | 2012-03-28 | 2014-06-18 | 中山市仁合药业有限公司 | Method for preparing esomeprazole and sodium salt thereof |
CN102659763B (en) * | 2012-04-27 | 2014-01-22 | 南京优科生物医药研究有限公司 | Method for synthesizing and purifying dexlansoprazole |
CN103044402B (en) * | 2012-12-31 | 2015-01-14 | 康普药业股份有限公司 | Method for synthesizing esomeprazole sodium |
CN103113351B (en) * | 2013-03-08 | 2015-01-21 | 苏州特瑞药业有限公司 | Method for preparing optically pure chiral sulfoxide compound |
CN104177336A (en) * | 2013-05-28 | 2014-12-03 | 上海汇伦生命科技有限公司 | Method for antipodal selective synthesis of (R)-lansoprazole |
WO2015155307A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
WO2015155281A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
EP2980086B1 (en) | 2014-07-29 | 2016-06-15 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Efficient process for the preparation of esomeprazole (S)-binol complex |
EP3239146A4 (en) * | 2014-12-26 | 2018-05-30 | The University of Tokyo | Method for producing proton pump inhibitor compound having optical activity |
CN104610226A (en) * | 2014-12-31 | 2015-05-13 | 广东东阳光药业有限公司 | Asymmetric oxidation method for dexlansoprazole |
EP3064495B1 (en) | 2015-03-06 | 2016-12-14 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of optically pure esomeprazole |
CN105218392B (en) * | 2015-07-09 | 2017-11-21 | 天津青松华药医药有限公司 | D winestone acid monoester monoamides class compounds |
CN105218391B (en) * | 2015-07-09 | 2017-11-21 | 天津青松华药医药有限公司 | L winestone acid monoester monoamides class compounds |
CN105968097B (en) * | 2016-05-17 | 2019-05-03 | 杭州华东医药集团新药研究院有限公司 | The industrialized preparing process of L-pantoprazole |
CN106083818A (en) * | 2016-06-08 | 2016-11-09 | 扬子江药业集团有限公司 | A kind of preparation method of high-purity esomeprazole sodium |
CN106366070B (en) * | 2016-08-10 | 2019-06-11 | 上海万巷制药有限公司 | A kind of preparation method of high-purity esomeprazole sodium |
CN106632249A (en) * | 2016-09-30 | 2017-05-10 | 青岛云天生物技术有限公司 | Method for preparing (S)-pantoprazole sodium |
CN106632248A (en) * | 2016-09-30 | 2017-05-10 | 青岛云天生物技术有限公司 | Preparation process of (S)-pantoprazole sodium |
CN106866630B (en) * | 2017-04-01 | 2018-08-07 | 上海华源医药科技发展有限公司 | A kind of preparation method of R-lansoprazole |
CN110746428A (en) * | 2019-10-29 | 2020-02-04 | 株洲千金药业股份有限公司 | Preparation method of R-type chiral sulfoxide compound |
CN110698482A (en) * | 2019-10-29 | 2020-01-17 | 株洲千金药业股份有限公司 | Preparation method of S-type chiral sulfoxide compound |
CN113845510A (en) * | 2020-06-27 | 2021-12-28 | 鲁南制药集团股份有限公司 | Preparation method of esomeprazole |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
DE4035455A1 (en) * | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | ENANTIOMER SEPARATION |
SE9301830D0 (en) * | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
SE504459C2 (en) * | 1994-07-15 | 1997-02-17 | Astra Ab | Process for the preparation of substituted sulfoxides |
GB9423970D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Oxidation |
GB9423968D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
-
1994
- 1994-07-15 SE SE9402510A patent/SE504459C2/en not_active IP Right Cessation
-
1995
- 1995-07-03 DK DK95926068.8T patent/DK0773940T4/en active
- 1995-07-03 EE EE9700006A patent/EE03354B1/en unknown
- 1995-07-03 EP EP95926068A patent/EP0773940B2/en not_active Expired - Lifetime
- 1995-07-03 WO PCT/SE1995/000818 patent/WO1996002535A1/en active Search and Examination
- 1995-07-03 DE DE69530987T patent/DE69530987T3/en not_active Expired - Lifetime
- 1995-07-03 RU RU97102162/04A patent/RU2157806C2/en active
- 1995-07-03 KR KR1019970700221A patent/KR100356252B1/en not_active IP Right Cessation
- 1995-07-03 SI SI9530676T patent/SI0773940T2/en unknown
- 1995-07-03 ES ES95926068T patent/ES2199998T5/en not_active Expired - Lifetime
- 1995-07-03 CA CA002193994A patent/CA2193994C/en not_active Expired - Lifetime
- 1995-07-03 MX MX9700358D patent/MX9700358A/en unknown
- 1995-07-03 BR BR9508292A patent/BR9508292A/en not_active Application Discontinuation
- 1995-07-03 PT PT95926068T patent/PT773940E/en unknown
- 1995-07-03 JP JP50493896A patent/JP3795917B2/en not_active Expired - Fee Related
- 1995-07-03 AU AU29948/95A patent/AU688074B2/en not_active Expired
- 1995-07-03 US US08/492,087 patent/US5948789A/en not_active Expired - Lifetime
- 1995-07-03 AT AT95926068T patent/ATE242233T1/en active
- 1995-07-03 UA UA97020638A patent/UA47409C2/en unknown
- 1995-07-03 SK SK48-97A patent/SK284059B6/en not_active IP Right Cessation
- 1995-07-04 TW TW084106875A patent/TW372971B/en not_active IP Right Cessation
- 1995-07-05 PL PL95318165A patent/PL186342B1/en unknown
- 1995-07-05 HU HU9700108A patent/HU226361B1/en unknown
- 1995-07-05 CN CN95194956A patent/CN1070489C/en not_active Expired - Lifetime
- 1995-07-05 CZ CZ0006497A patent/CZ297987B6/en not_active IP Right Cessation
- 1995-07-05 NZ NZ289959A patent/NZ289959A/en not_active IP Right Cessation
- 1995-07-06 IL IL11447795A patent/IL114477A/en not_active IP Right Cessation
- 1995-07-10 MA MA23950A patent/MA23611A1/en unknown
- 1995-07-10 ZA ZA955724A patent/ZA955724B/en unknown
- 1995-07-11 EG EG57195A patent/EG24534A/en active
- 1995-07-11 DZ DZ950088A patent/DZ1911A1/en active
- 1995-07-12 HR HR950401A patent/HRP950401B1/en not_active IP Right Cessation
- 1995-07-13 TN TNTNSN95081A patent/TNSN95081A1/en unknown
- 1995-07-14 YU YU47695A patent/YU49475B/en unknown
- 1995-07-14 TR TR95/00861A patent/TR199500861A2/en unknown
- 1995-07-14 MY MYPI95001998A patent/MY113180A/en unknown
- 1995-10-07 SA SA95160294A patent/SA95160294B1/en unknown
-
1996
- 1996-06-28 AR ARP960103398A patent/AR003443A1/en active IP Right Grant
- 1996-12-27 IS IS4406A patent/IS1772B/en unknown
-
1997
- 1997-01-10 FI FI970102A patent/FI117672B/en not_active IP Right Cessation
- 1997-01-10 FI FI970102D patent/FI117830B/en active
- 1997-01-14 NO NO19970153A patent/NO312101B1/en not_active IP Right Cessation
-
1998
- 1998-07-17 HK HK98109230A patent/HK1008331A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU97102162A (en) | METHOD OF SYNTHESIS OF SUBSTITUTED SULPHOXIDES | |
KR970704731A (en) | Process for Synthesis of Substituted Sulphoxides | |
DE60124692T2 (en) | PROCESS FOR PREPARING OPTIC-ACTIVE SULFOXIDE DERIVATIVES | |
JP4612542B2 (en) | Process for the production of optically pure active compounds | |
IL168554A (en) | Process for preparing s-pantoprazole | |
JP2007523152A5 (en) | ||
CA2276753A1 (en) | New process | |
ATE363480T1 (en) | ALKYLAMMONIUM SALTS OF OMEPRAZOLE AND ESOMEPRAZOLE | |
JP2007521314A (en) | Process for producing isomeric pure prodrugs of proton pump inhibitors | |
CN101323609B (en) | Method for synthesizing high antipode content benzimidazole derivative by unsymmetrical oxidizing thioether into sulphoxide | |
ATE382047T1 (en) | OPTICALLY ACTIVE QUINOLINE CARBONIC ACID DERIVATIVES HAVING A 7-PYRROLIDINE SUBSTITUENT CAUSING THE OPTICAL ACTIVITY AND A METHOD FOR THE PRODUCTION THEREOF | |
US20070225500A1 (en) | Process for the Preparation of Pyridin-2-Ylmethylsulphinyl-1H-Benzimidazol Compounds | |
KR20070031945A (en) | Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds | |
ITMI20091838A1 (en) | ASYMMETRIC SYNTHESIS PROCESS OF ESOMEPRAZOLE AND ITS SALTS |